• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mediwound Ltd Ord Sh (NQ: MDWD )

    15.77 -1.22 (-7.18%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 106,829
    Open 16.79
    Bid (Size) 15.77 (4)
    Ask (Size) 15.95 (4)
    Prev. Close 16.99
    Today's Range 15.47 - 16.91
    52wk Range 7.100 - 18.75
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MediWound Ltd. (NASDAQ: MDWD) Sets New 52-Week High in Wednesday Session
    Via Investor Brand Network
    MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023
    MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
    Via InvestorPlace

    Performance

    YTD
    +40.18%
    +40.18%
    1 Month
    +0.25%
    +0.25%
    3 Month
    +21.12%
    +21.12%
    6 Month
    +99.62%
    +99.62%
    1 Year
    +26.97%
    +26.97%

    More News

    Read More
    MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
    From MediWound Ltd.
    Via GlobeNewswire
    Preview: MediWound's Earnings
    Via Benzinga
    MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
    From MediWound Ltd.
    Via GlobeNewswire
    Recap: MediWound Q3 Earnings
    Via Benzinga
    Earnings Outlook For MediWound
    Via Benzinga
    HC Wainwright & Co. Maintains Buy Rating for MediWound: Here's What You Need To Know
    Via Benzinga
    Earnings Scheduled For March 21, 2024
    Via Benzinga
    MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound to Participate in Two Upcoming Investor Conferences
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
    From MediWound Ltd.
    Via GlobeNewswire
    Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development
    Via Benzinga
    MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
    From MediWound Ltd.
    Via GlobeNewswire
    Earnings Scheduled For November 21, 2023
    Via Benzinga
    MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound to Report Third Quarter 2023 Financial Results
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Deploys NexoBrid® for Emergency Supply
    From MediWound Ltd.
    Via GlobeNewswire
    Q4 Stock Predictions: 3 Micro-Cap Stocks Ready to Skyrocket Into 2024
    Via InvestorPlace
    MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
    From MediWound Ltd.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.